Savara to Present Molgramostim Data at CHEST 2026 Conference

what happened

Newsmetry API reports that Savara Inc. announced the acceptance of an encore oral presentation covering Phase 3 IMPALA-2 data and a poster presentation on the Phase 2/3 IMPALA trial. Both presentations will be held at CHEST 2026 in Phoenix, Arizona, from October 18–21.

The oral session will address long-term efficacy and safety of molgramostim during the open-label treatment period of IMPALA-2. It is scheduled for October 20, from 1:45 to 2:30 PM MST, at the Phoenix Convention Center. Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine, will present the data. The poster on treatment effects in patients with mild diffusion impairment is set for October 21, from 10:20 to 11:05 AM MST.

Trapnell will also participate in a learning-theatre session on autoimmune pulmonary alveolar proteinosis and the patient experience on October 20, from 12:30 to 1:15 PM MST. Patients Eric and Karli are also listed as speakers.

Autoimmune PAP is a rare lung disease in which surfactant builds up in the alveoli and impairs gas transfer. Molgramostim is a recombinant human GM-CSF in Phase 3 development and is delivered through the investigational eFlow® Nebulizer System developed by PARI Pharma GmbH.

why it matters

The announcement sets out when investors can expect additional clinical information on molgramostim, including long-term IMPALA-2 data and findings from the IMPALA study.

instruments